TargetCancer Foundation’s funded research in rare cancers has yielded groundbreaking discoveries published in numerous peer-reviewed journals. This consistent contribution to rare cancer knowledge underscores our commitment to expertise, authoritative research, and trustworthy information in the rare cancer community.
Featured Publication
“Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment” JCO Precision Oncology – Read Article
Paired exome analysis of Barrett’s esophagus and adenocarcinoma
July 2015Nature Genetics
Epithelial PD-L2 expression marks Barrett’s Esophagus and Esophageal Adenocarcinoma
June 2015Cancer Immunology Research
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression
March 2015Cell Reports
IDH mutations in liver cell plasticity and biliary cancer
November 2014Cell Cycle
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
September 2014Nature
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
March 2014Genes and Development
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity
November 2012Nature Genetics
Kras-G12D and p53 Mutation Cause Primary Intrahepatic Cholangiocarcinoma
January 2012Cancer Research